Aggregator

Observational studies suggested the vaccine could do double duty but a randomized trial shows no benefit

Certain shallow-water species carry a mutation that reduces translation errors and prevents toxic protein buildup

Mix-up in distance scales may explain hints of anisotropy in distribution of galaxies

Publisher denies a bot was to blame for withdrawing famed physicist’s work

Scientists at the University of Illinois Chicago have turned an unlikely source into a potential new weapon against cancer: bacteria that naturally live inside tumors. They developed a peptide called aurB, inspired by a bacterial protein, that infiltrates cancer cells and effectively cuts off their energy supply by targeting the mitochondria—the cells’ power plants.

Almost half of the takeaway meals tested contained more salt than advertised, with some dishes delivering nearly twice the recommended daily limit in a single serving. Surprisingly, classic fish and chips ranked among the lowest-salt options, while pasta, pizza, and curries were often the saltiest.

Alzheimer's disease (AD) remains a progressive neurodegenerative disorder without effective disease-modifying therapies. Epidemiological evidence indicates that regular resistance exercise substantially reduces AD risk, an effect potentially mediated by insulin-like growth factor-1 (IGF-1). However, the complete mechanistic pathway from exercise-induced peripheral IGF-1 synthesis to its central neuroprotective actions has not been systematically integrated. This review provides a comprehensive...

Bridge-like lipid transfer proteins (BLTPs) play fundamental roles in cellular lipid redistribution between organellar membranes. They comprise bridge domains spanning organelles at contact sites that allow lipids to transit through the cytosol between adjacent membranes. The assembly of BLTPs into complexes with adaptor proteins enables lipid transfer. To address the mechanisms underlying the assembly and regulation of BLTP complexes, we used cryo-EM to resolve the structure of one such BLTP,...

There is growing evidence that long-acting mimetics of the gut-derived incretin hormones GLP-1 and GIP act as disease-modifying therapies for Alzheimer's disease (AD). Here, we temporally characterize the efficacy of the approved incretin receptor agonists semaglutide, a GLP-1R agonist, and tirzepatide, a GLP-1R/GIPR co-agonist, in preventing AD progression. In 5xFAD mice treated for 2 or 4 months, both incretin therapies lower body weight and improve glucose tolerance, yet neither compound...

CONCLUSIONS: Conclusions are limited by substantial heterogeneity in the assessment of frailty, sarcopenia, AD biomarkers, and a lack of longitudinal data. Future studies are needed that include longitudinal analyses, consensus in AD biomarker, frailty and sarcopenia assessments, and incorporation of novel AD biomarkers, in particular tau and neuroinflammation, to help clarify these relationships.

Clinical trial design (CTD) is a time-consuming process that requires substantial domain expertise. Large-scale real-world data (RWD), such as electronic health records (EHR), encodes practice-based evidence that is of tremendous value to CTD. In recent years, many machine learning methods have been developed to extract such real-world evidence (RWE) from the RWD to inform CTD, but they still need to be communicated with the domain experts extensively in an iterative manner to be further refined...